Epkinly Injection, Solution
NDC 82705-010
Product Information
Epkinly (epcoritamab-bysp) is a BLA-approved product labeled by Genmab Us, Inc.. This medication is typically used as a bispecific cd20-directed cd3 t cell engager [epc]. It is supplied as a injection, solution for subcutaneous administration. This product entry covers the primary NDC 82705-010 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 82705-010?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- EPCORITAMAB (UNII: D6OMY2L0WA)
- EPCORITAMAB (UNII: D6OMY2L0WA) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ACETIC ACID (UNII: Q40Q9N063P)
- SORBITOL (UNII: 506T60A25R)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- SODIUM ACETATE (UNII: 4550K0SC9B)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2637399 - epcoritamab-bysp 48 MG in 0.8 ML Injection
- RxCUI: 2637399 - 0.8 ML epcoritamab-bysp 60 MG/ML Injection
- RxCUI: 2637399 - epcoritamab-bysp 48 MG per 0.8 ML Injection
- RxCUI: 2637405 - epkinly 48 MG in 0.8 ML Injection
- RxCUI: 2637405 - 0.8 ML epcoritamab-bysp 60 MG/ML Injection [Epkinly]
Which are the Pharmacologic Classes of this product?
- Bispecific CD20-directed CD3 T Cell Engager - [EPC] (Established Pharmacologic Class)
- CD20-directed Antibody Interactions - [MoA] (Mechanism of Action)
- CD3 Receptor Agonists - [MoA] (Mechanism of Action)
- CD3-directed Antibody Interactions - [MoA] (Mechanism of Action)
- Cytochrome P450 Inhibitors - [MoA] (Mechanism of Action)
- Increased Cytokine Activity - [PE] (Physiologic Effect)
* Please review the full disclaimer at the bottom of this page.